HLA-A*02:07 is a protective allele for EBV negative and a susceptibility allele for EBV positive classical Hodgkin lymphoma in China

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Huang, Xin ^a,b   Hepkema, Bouke ^a   Nolte, Ilja ^a   Kushekhar, Kushi ^a   Jongsma, Theo ^a   Veenstra, Rianne ^a   Poppema, Sibrand ^a   Gao, Zifen ^b   Visser, Lydia ^a   Diepstra, Arjan ^a   van den Berg, Anke ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A2 ANTIGEN; DNA;

ALLELE; ARTICLE; CANCER SUSCEPTIBILITY; CHINA; CLASSICAL HODGKIN LYMPHOMA; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HLA TYPING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PHENOTYPE; PROTECTION; ASIAN; CASE CONTROL STUDY; COMPARATIVE STUDY; EPSTEIN BARR VIRUS INFECTION; GENE FREQUENCY; GENETICS; GENOTYPE; HODGKIN DISEASE; IMMUNOLOGY; ISOLATION AND PURIFICATION; PATHOGENICITY; REAL TIME POLYMERASE CHAIN REACTION; VIROLOGY;

HUMAN HERPESVIRUS 4;

ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; DNA; EPSTEIN-BARR VIRUS INFECTIONS; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HERPESVIRUS 4, HUMAN; HLA-A2 ANTIGEN; HODGKIN DISEASE; HUMANS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84857100518     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031865     Document Type: Article

References (25)

1. Ambinder RF, (2007) Epstein-barr virus and Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program pp. 204-209.
2. Poppema S, (1996) Immunology of Hodgkin's disease. Baillieres Clin Haematol 9 (3): 447-457.
3. Jarrett AF, Armstrong AA, Alexander E, (1996) Epidemiology of EBV and Hodgkin's lymphoma. Ann Oncol 7 (Suppl 4): 5-10.
4. Carbone A, Gloghini A, Serraino D, Spina M, (2009) HIV-associated Hodgkin lymphoma. Curr Opin HIV AIDS 4 (1): 3-10.
5. Hollsberg P, (2002) Contribution of HLA class I allele expression to CD8+ T-cell responses against Epstein-Barr virus. Scand J Immunol 55 (2): 189-195.
6. Voo KS, Fu T, Wang HY, Tellam J, Tellam J, Heslop HE, et al. (2004) Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes. J Exp Med 199 (4): 459-470.
7. Rickinson AB, Moss DJ, (1997) Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 15: 405-431.
8. Lee SP, Tierney RJ, Thomas WA, Brooks JM, Rickinson AB, (1997) Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. J Immunol 158 (7): 3325-3334.
9. Kruger S, Schroers R, Rooney CM, Gahn B, Chen SY, (2003) Identification of a naturally processed HLA-DR-restricted T-helper epitope in Epstein-Barr virus nuclear antigen type 1. J Immunother 26 (3): 212-221.
10. Straathof KC, Leen AM, Buza EL, Taylor G, Huls MH, et al. (2005) Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. J Immunol 175 (6): 4137-4147.
11. Niens M, Jarrett RF, Hepkema B, Nolte I, Diepstra A, et al. (2007) HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma. Blood 110 (9): 3310-3315.
12. Hjalgrim H, Rostgaard K, Johnson PC, Lake A, Shield L, et al. (2010) HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphoma. Proc Natl Acad Sci U S A 107 (14): 6400-6405.
13. Brennan RM, Burrows SR, (2008) A mechanism for the HLA-A*01-associated risk for EBV+ Hodgkin lymphoma and infectious mononucleosis. Blood 112: 2589-2590.
14. Krausa P, Brywka M III, Savage D, Hui KM, Bunce M, et al. (1995) Genetic polymorphism within HLA-A*02: significant allelic variation revealed in different populations. Tissue Antigens 45 (4): 223-231.
15. Browning M, Krausa P, (1996) Genetic diversity of HLA-A2: evolutionary and functional significance. Immunol Today 17 (4): 165-170.
16. Sudo T, Kamikawaji N, Kimura A, Date Y, Savoie CJ, et al. (1995) Differences in MHC class I self peptide repertoires among HLA-A2 subtypes. J Immunol 155: 4749-4756.
17. Cheng LH, Jin SZ, Gao SQ, Li Z, Zou HY, et al. (2005) Difference in HLA-A*02 allele distribution between Han populations in south and north China. Di Yi Jun Yi Da Xue Xue Bao 25 (3): 321-324.
18. Huang X, van den Berg A, Gao Z, Visser L, Nolte I, et al. (2010) Expression of HLA class I and HLA class II by tumor cells in Chinese classical Hodgkin lymphoma patients. PLoS One 5 (5): e10865.
19. Sidney J, del Guercio MF, Southwood S, Hermanson G, Maewal A, et al. (1997) The HLA-A*02:07 peptide binding repertoire is limited to a subset of the HLA-A*02:01 repertoire. Human Immunol 58: 12-20.
20. Sidney J, Southwood S, Mann DL, Fernandez-Vina MA, Newman MJ, et al. (2001) Majority of peptides binding HLA-A*0201 with high affinity crossreact with other A2-supertype molecules. Hum Immunol 62 (11): 1200-1216.
21. Khanna R, Burrows SR, Nicholls J, Poulsen LM, (1998) Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes. Eur J Immunol 28 (2): 451-458.
22. Hildesheim A, Apple RJ, Chen CJ, Wang SS, Cheng YJ, et al. (2002) Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst 94 (23): 1780-1789.
23. Chiang AK, Tao Q, Srivastava G, Ho FC, (1996) Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease. Int J Cancer 68 (3): 285-290.
24. Pasini E, Caggiari L, Dal Maso L, Martorelli D, Guidoboni M, et al. (2009) Undifferentiated nasopharyngeal carcinoma from a nonendemic area: protective role of HLA allele products presenting conserved EBV epitopes. Int J Cancer 125 (6): 1358-1364.
25. Burt RD, Vaughan TL, McKnight B, Davis S, Beckmann AM, et al. (1996) Associations between human leukocyte antigen type and nasopharyngeal carcinoma in Caucasians in the United States. Cancer Epidemiol Biomarkers Prev 5: 879-887.